Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

UBS Maintains Sell on Bed Bath & Beyond, Lowers Price Target to $13

UBS analyst Robin Farley maintains Bed Bath & Beyond (NASDAQ:BBBY) with a Sell and lowers the price target from $20 to $13.

byBenzinga Newsdesk

January 4, 2022

1 minute read

UBS analyst Robin Farley maintains Bed Bath & Beyond (NASDAQ:BBBY) with a Sell and lowers the price target from $20 to $13.

Analyst Ratings

Analyst Ratings For argenx

By Benzinga Insights

December 8, 12:23 PM

Analysts have provided the following ratings for argenx (NASDAQ:ARGX) within the last quarter:

ARGX

Needham Reiterates Buy on AgileThought, Maintains $7 Price Target

By Benzinga Newsdesk

March 10, 8:06 AM

Needham analyst Mayank Tandon reiterates AgileThought (NASDAQ:AGIL) with a Buy and maintains $7 price target.

AGIL

IPOs
News

Lichen China Limited Announces Pricing Of $16M Initial Public Offering Of 4M Shares At A Price Of $4/Share

By Happy Mohamed

February 6, 9:11 AM

Lichen China Limited (the "Company" or "Lichen China"), a dedicated financial and taxation service provider in China, today announced the pricing of its initial public offering (the

LICN

Craig-Hallum Downgrades Joint to Hold, Announces $30 Price Target

By Benzinga Newsdesk

May 6, 10:11 AM

Craig-Hallum analyst Jeremy Hamblin downgrades Joint (NASDAQ:JYNT) from Buy to Hold and announces $30 price target.

JYNT

UBS Maintains Sell on Bed Bath & Beyond, Lowers Price Target to $13

Related Posts

Analyst Ratings For argenx

Needham Reiterates Buy on AgileThought, Maintains $7 Price Target

Lichen China Limited Announces Pricing Of $16M Initial Public Offering Of 4M Shares At A Price Of $4/Share

Craig-Hallum Downgrades Joint to Hold, Announces $30 Price Target